Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8142603 | 0.86 | TSHR (0.73) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL680052 | 0.84 | ALDH1A1 (0.69) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL1503956 | 0.83 | TSHR (0.69) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL9863064 | 0.83 | TSHR (0.69) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL9416709 | 0.83 | TSHR (0.56) | TSHRMAPTMEN1CASP3KMT2A | |
| SCHEMBL11429211 | 0.83 | TSHR (0.69) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL16477197 | 0.83 | TSHR (0.69) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL2105705 | 0.83 | TSHR (0.69) | TSHRMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL679125 | 0.83 | TSHR (0.69) | TSHRMAPTALDH1A1GAASMN1; SMN2 | |
| SCHEMBL28709827 | 0.83 | TSHR (0.64) | TSHRMAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-04-09 | — | — | US | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-116685324-A | Pharmaceutical composition for preventing or treating pancreatic cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116390729-A | Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-111032643-B | Quinolinone compounds | 詹森药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-112739691-B | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2010011538-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2007118853-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2007-10-25 | — | — | WO | disclosed |
| CN-1029958-C | Malonic acid derivative applied to hold back plant growth | UNION CARBIDE AGRICULT (US) | 1995-10-11 | — | — | CN | disclosed |
| US-5292937-A | Use of malonic acid derivative compounds for retarding plant growth | RHONE-POULENC INC. (US) | 1994-03-08 | — | — | US | disclosed |
| US-5123951-A | Ethylene response inducing agent and malonic acid derivative | RHONE-POULENC NEDERLAND B.V. (NL) | 1992-06-23 | — | — | US | disclosed |
| CN-87103552-A | Adopt malonate derivative to improve crop yield | — | 1988-07-06 | — | — | CN | disclosed |
| CN-87103683-A | Use of malonic acid derivatives for retarding plant growth | — | 1988-05-11 | — | — | CN | disclosed |
| EP-0262209-A1 | SYNERGISTIC PLANT GROWTH REGULATOR COMPOSITIONS. | RHONE POULENC BV (NL) | 1988-04-06 | — | — | EP | disclosed |
| CN-87103565-A | SYNERGISTIC PLANT GROWTH REGULATOR COMPOSITIONS | — | 1988-03-02 | — | — | CN | disclosed |
| WO-1987005781-A2 | SYNERGISTIC PLANT GROWTH REGULATOR COMPOSITIONS | RHONE-POULENC NEDERLANDS B.V. (NL) | 1987-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | NTRK1, NTRK3, MUSK | TSHR 372/4885MAPT 1401/4885MEN1 3990/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | TSHR 472/4885MAPT 833/4885MEN1 420/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | TSHR 526/4885MAPT 767/4885MEN1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.